Clinical and therapeutic aspects of congenital and acquired long QT syndrome

American Journal of Medicine

Volumn 112, Issue 1, 2002, Pages 58-66

  Khan, Ijaz A ^a,b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ARSENIC TRIOXIDE; ASTEMIZOLE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; FLECAINIDE; HALOPERIDOL; ISOPRENALINE; KETANSERIN; MAGNESIUM SULFATE; MEXILETINE; PAPAVERINE; PHENOTHIAZINE DERIVATIVE; POTASSIUM; POTASSIUM CHANNEL STIMULATING AGENT; PROBUCOL; PROPRANOLOL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TACROLIMUS; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; ARTIFICIAL HEART PACEMAKER; AUTONOMIC NEUROPATHY; BRADYCARDIA; DEFIBRILLATOR; DISEASE COURSE; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; FLUSHING; GENE LOCUS; GENETIC SCREENING; HEART INFARCTION; HEART PACING; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG QT SYNDROME; LONG TERM CARE; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QT INTERVAL; RECURRENT DISEASE; SIDE EFFECT; SODIUM CURRENT; SPONTANEOUS MUTATION; STROKE; SUBARACHNOID HEMORRHAGE; SUDDEN DEATH; SYMPATHECTOMY; SYNCOPE; TORSADE DES POINTES; VERTIGO;

HUMANS; LONG QT SYNDROME;

EID: 0036155193     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)01011-7     Document Type: Article

References (88)

1. QT-interval changes with age in an overtly healthy population
2. Diurnal pattern of QTc interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events
3. The long QT syndrome: Prospective longitudinal study of 328 families
4. Influence of genotype on the clinical course of the long QT syndrome
5. Molecular biology and the prolonged QT syndromes
6. Molecular biology of K(+) channels and their role in cardiac arrhythmias
7. Molecular biology of sodium channels and their role in cardiac arrhythmias
8. Calcium currents and arrhythmias: Insights from molecular biology
9. Congenital deaf-mutism, functional heart disease with prolongation of QT interval and sudden death
10. Aritmie cardiache rare dell'eta pediatrica
11. A new familial cardiac syndrome in children
12. The QT prolongation syndrome: Long-term follow-up study of 13 families with Romano-Ward syndrome
13. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene
14. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielson cardioauditory syndrome
15. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
16. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome
17. Mapping of a gene for long QT syndrome to chromosome 4q25-27
18. Ks function
19. Kr potassium channels with HERG and is associated with cardiac arrhythmia
20. Molecular genetics of inherited long QT syndromes
21. Spectrum of mutations in long QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2
22. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology
23. A structural basis for drug-induced long QT syndrome
24. Electrophysiological remodeling in hypertrophy and heart failure
25. Ventricular arrhythmias and hypokalemia
26. Torsade de pointes induced by hypocalcemia in a postoperative patient with thyrotoxicosis
27. Relation between QT, and RR intervals in patients with bradyarrhythmias
28. Cocaine-induced torsade de pointes in idiopathic long QT syndrome
29. Cardiac manifestations of acute carbamate and organophosphate poisoning
30. Torsade de pointes as a complication of subarachnoid hemorrhage: A critical reappraisal
31. Cardiac effects of starvation and semistarvation diets: Safety and mechanisms of action
32. Sudden unexplained cardiac death in avid dieters using the liquid-protein-modified-fast diet: Observations in 17 patients and the role of the prolonged QT interval
33. Prolonged QT period in diabetic autonomic neuropathy. A possible role on sudden cardiac death
34. Long QTc and torsade de pointes in human immunodeficiency virus disease
35. Torsade de pointes: A case with multiple variables
36. Dispersion of the QT interval: A marker of therapeutic efficacy in the idiopathic long QT syndrome
37. Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome
38. Value of Holter monitoring in patients with long QT syndrome
39. Electrical alternation of the T wave: Clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long QT syndrome
40. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome
41. Spectrum of ST-T-wave patterns, and repolarization parameters in congenital long QT syndrome: ECG findings identify genotypes
42. Long QT syndrome presenting as a seizure
43. Twelve-lead electrocardiogram of torsade de pointes
44. Age-gender influence on the rate-corrected QT interval, and the QT-heart rate relation in families with genotypically characterized long QT syndrome
45. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs
46. Increased propensity of women to develop torsade de pointes during complete heart block
47. Mechanisms in adrenergic dependent onset of torsade de pointes
48. Mode of onset of torsade de pointes in congenital long QT syndrome
49. Idiopathic long QT syndrome: Progress and questions
50. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest
51. Prolonged QT interval predicts cardiac, and all-cause mortality in the elderly: The Rotterdam Study
52. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome
53. Auditory stimuli as a trigger for arrhythmic events differentiates HERG-related (LQT2) patients from KVLQT1-related patients
54. Genotype-phenotype correlation in the long QT syndrome: Gene-specific triggers for life-threatening arrhythmias
55. Genotype and severity of long QT syndrome
56. Diagnostic criteria for the long QT syndrome: An update
57. Rate adaptation of QT intervals during and after exercise in children with congenital long QT syndrome
58. Polymorphic ventricular tachycardia: Clinical characterization, therapy, and the QT interval
59. The long QT syndrome: A critical review, new clinical observation and a unifying hypothesis
60. Torsade de pointes therapy with phenytoin
61. Treatment of torsade de pointes with magnesium sulphate
62. Torsade de pointes and atrioventricular block
63. Magnesium suppression of early afterdepolarizations and ventricular arrhythmias induced by cesium in dogs
64. Genetically defined therapy of inherited long QT syndrome: Correction of abnormal repolarization by potassium
65. Overdrive pacing in quinidine syncope and other long QT interval syndromes
66. Effects of pacing on triggered activity induced by early afterdepolarizations
67. Polymorphic ventricular tachycardia: Clinical features and treatment
68. Prevention of ventricular arrhythmias in the congenital long QT syndrome
69. Effectiveness and limitations of beta-blocker therapy in congenital long QT syndrome
70. Cardiac pacing in the long QT syndrome: Review of available data and practical recommendations
71. Permanent cardiac pacing in patients with the long QT syndrome
72. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome
73. Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome
74. Rate smoothing with cardiac pacing for preventing torsade de pointes
75. The automatic implantable cardioverter-defibrillator in young patients
76. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome: A worldwide report
77. Pharmacological targeting of long QT mutant sodium channels
78. Effect of flecainide in patients with new SCN5A mutation: Mutation specific therapy for long QT syndrome
79. Long QT syndrome patients with mutations of the SCN5A, and HERG genes have differential responses to Na channel blockade and to increases in heart rate: Implications for gene specific therapy
80. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long QT syndrome
81. Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine
82. Ventricular tachyarrhythmias related to early afterdepolarizations and triggered firing: Relationship to QT interval prolongation and potential therapeutic role for calcium channel blocking agents
83. Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome
84. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty
85. The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome
86. The long QT syndrome in children: An international study of 287 patients
87. The long QT syndrome
88. The inherited long QT syndrome: From ion channel to bedside